Article Sidebar

Submitted
14 August 2017
Accepted
14 August 2017
Published
15 August 2017
Download
PDF
Statistic
Read Counter : 905 Download : 520

Main Article Content

Abstract

Treatment with RT Inhibitors has been used as first line program in Mimika. Regular use of antiretroviral drugs can lower the amount of the virus, but after that HIV can become resistant to the drugs given. Viral resistance to the drugs can occur because of a mutation. If the resistance-associated mutations occur in the DNA of the virus, then the ARV provided will no longer be effective. The aim of this study was to identify the presence of resistance-associated mutations in DNA fragment that encodes the protease and reverse transcriptase. This study used cross sectional design with 84 subjects who had received antiretroviral for > 6 months. The study was conducted in Mitra Masyarakat Mimika Hospital. Laboratory process included extraction, RT-PCR, electrophoresis and sequencing. Data analysis used resistance interpretation algorithms in HIV Database. Results showed that 1 subject who did not receive protease therapy was identified as having minor mutation L10V, 1 subjects receiving NRTI inhibitors had mutation M184V motive and 1 subjects with M41L motive and 1 subjects who received NNRTI inhibitor therapy identified as having mutated Y181C and V108I motive. In conclusion, mutant HIV-1 related to ARV resistance has been identified in two subjects who had received antiretroviral therapy in Mitra Masyarakat Mimika Hospital.

Keywords

mutation HIV-1 Mimika protease Rtase

Article Details

License

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial — You may not use the material for commercial purposes.

    ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share — copy and redistribute the material in any medium or format.

    Adapt — remix, transform, and build upon the material.

How to Cite
Widiyanti, M., Fitriana, E., Natalia, E. I., & Wike, I. (2017). IDENTIFICATION OF ANTIRETROVIRAL MUTATION IN PROTEASE AND REVERSE TRANCRIPTASE INHIBITOR IN HUMAN IMMUNODEFICIENCY VIRUS-1 OF HIV/AIDS PATIENTS IN MIMIKA REGENCY, PAPUA. Folia Medica Indonesiana, 53(1), 56–63. https://doi.org/10.20473/fmi.v53i1.5491
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Arts, JE and D.J. Hasuda. HIV-1 Antiretroviral Drug Theraphy, cshperspect. A007161. 2012
  2. Beck, I. A, M. Mahalanabis, G. Pepper, A. Wright, S. Hamilton, E. Langston, and L. M. Frenkel. A rapid and sensitive oligonucleotide ligation assay for the detection of mutations in human immunodeficiency virus type 1 associated with high- level resistance to protease inhibitors. J. Clin. Microbiol. 2002. 40:1413-1419.
  3. Boyer PL, Hughes SH, Effects of Amino Acid Substitution at position 115 on the Fidelity of Human Immunodeficiency Virus Type 1 Reverse Transcrip-tase. J Virol .2000. 74(14):6494-500
  4. Daniel R and Kuritzkes MD. HIV Resistance : frequency, testing, mechanism, recommendation of an international AIDS Society-USA, Top HIV Med. 2007;15(5):150-4
  5. Dinas Kesehatan Provinsi Papua. Laporan Perawatan HIV-ART Tahun 2011
  6. Direktorat Jenderal Pemberantasan Penyakit Menular dan Penyehatan Lingkungan. 2014. Statistik Kasus HIV/AIDS di Indonesia. Kementerian Kesehatan RI. Jakarta
  7. Direktorat Pengendalian Penyakit dan Penyehatan Ling-kungan Departemen Kesehatan RI. Pedoman Nasional Terapi Antiretroviral. Jakarta, 2004
  8. Direktorat Pengendalian Penyakit dan Penyehatan Lingkungan Departemen Kesehatan RI. Pedoman Nasional Perawatan, Dukungan dan Pengobatan bagi ODHA : Buku Pedoman untuk Petugas Kesehatan dan Petugas Lainnya. Jakarta, 2006
  9. Direktorat Pengendalian Penyakit dan Penyehatan Lingkungan. Laporan Perkembangan Situasi Perkem-bangan HIV&AIDS di Indonesia pada Triwulan II Tahun 2011. www.aidsina.or.id Diunduh pada tanggal 10 Juni 2016
  10. Johnson VA, Calvez V, Gunthard HF, Update of the drug resistance mutations in HIV-1 Top Antivir Med. 2013. 21:6-14
  11. Khairunnisa SQ, Kotaki T, Witaningrum AM, Yunifiar MQ, Sukartiningrum SD, Nasronoudin, Kameoka M. Appearance of Drug Resistance-Associated Mutations in Human Immunodefoceciency Virus Type 1 Protease and Reverse Transcriptase Derived from Drug-Treated Indonesian Patients. AIDS Research and Human Retroviruses. 2014. 30:1-6
  12. Lameshow S, Homer DW, Klar J, Lawn SK. Besar Sampel dalam Penelitian Kesehatan. Gadjah Mada University Press. Jogjakarta. 1997
  13. Lodish H, Berk A, Matsudara P, Kaiser C, Kreiger M, Scott MP, Zipursky SL, Darnell J. Moleculer Genetic Techniques and Genomics In : Molecular Cell Biology. 5th. Ed. Pp : 372-74. W.H. Freeman and Company. New York. 2003
  14. Markowitz M, Louie M, Hurley A. A novel antiviral intervention result in more accurate assessment of Human Immunodeficiency Virus Type 1 replication Dynamic an T-cell decay in vivo. J Virol. 2003. 77: 5073-8
  15. Mulder J, Resnick R, Saget B, Scheibel S, Herman S, Payne H, Harrigan R & Kwok S. A Rapid and Simple Method for Extracting human immunodeficiency virus type 1 RNA from Plasma; enhanced sensitivity. Jour-nal of Clinical Microbiology. 1997. 35(5):1278-80
  16. Petrella M, Maureen O, Daniela M, Differential Maintenance of the M184V substitution in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 by various Nucleoside Antiretroviral Agents in tissue Culture, ASM. 2004. 48(11):4189-94.
  17. Sambrook J, Russel DW. Molecular cloning : a labora-tory Manual. 3rd ed. Cold Spring Harbor Laboratory Press. New York. 2001
  18. Santoro MM and Perno CF. Review Article HIV-1 Genetic Variability and Clinical Implications. ISRN Microbiology. 2013. 2013: 1-20
  19. Tisdale M, Kemp SD, Parry NR, Larder B. Rapid in vitro selection of human immunodefocoency virus type 1 resistant to 3’-thiacytidine inhibitors due to a mutation in the YMMD region of reverse transcrip-tase. Proc Natl Acad Sci USA. 1993. 90(12):5653-56
  20. Victoria A, Johnson, Francoise, Clotet B, Gunthard HF, Daniel R, Kuritzkes, Pillay D, Schapiro JM. Updated of the drug resistance mutation in HIV-1. Recom-mendation of an International AIDS Society-USA, Top HIV Med. 2008 : 165(5):138-45
  21. Victoria A. Special Contribution : Update of the Drug Resistance Mutations in HIV-1 : December 2010. Topics in HIV Medicine. 2010. 18:156-63
  22. Victoria AJ. Update of the Drug Resistance Mutation in HIV-1. Topics in HIV Medicine. 2006. 14(3):125-28.

Most read articles by the same author(s)